SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-23-216053
Filing Date
2023-08-18
Accepted
2023-08-18 17:16:27
Documents
1
Group Members
ASTELLAS GENE THERAPIES, INC. (F/K/A AUDENTES THERAPEUTICS, INC.)ASTELLAS US HOLDING, INC.

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d545596dsc13da.htm SC 13D/A 114155
  Complete submission text file 0001193125-23-216053.txt   115777
Mailing Address 2-5-1, NIHONBASHI-HONCHO CHUO-KU TOKYO M0 103-8411
Business Address 2-5-1, NIHONBASHI-HONCHO CHUO-KU TOKYO M0 103-8411 81-3-3244-3231
Astellas Pharma Inc. (Filed by) CIK: 0001376684 (see all company filings)

IRS No.: 132971791
Type: SC 13D/A

Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Subject) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91724 | Film No.: 231186706
SIC: 2836 Biological Products, (No Diagnostic Substances)